Thus, combining low-dose TSA with anti-PD-L1 treatment, which led to tumor reduction and extended survival in mice, suggests a potential strategy to augment anti-tumor macrophage efficacy [201, 202]. The gene discussed is CD274; the disease is neoplasm.